BEIJING LUZHU BIOTECHNOLOGY CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.5 HKD | +3.69% |
|
+0.22% | -24.75% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 5,502 | 4,088 | - | - |
| Enterprise Value (EV) 1 | 5,502 | 3,589 | 3,824 | 4,099 |
| P/E ratio | -21.7 x | -12.5 x | -12.2 x | -16 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 3,586 x | 40.8 x | 13.2 x |
| EV / Revenue | - | 3,148 x | 38.2 x | 13.2 x |
| EV / EBITDA | - | -11.8 x | -15.5 x | -48.2 x |
| EV / FCF | -20 x | -13.4 x | -15.7 x | -17.7 x |
| FCF Yield | -5.01% | -7.48% | -6.37% | -5.64% |
| Price to Book | 5.39 x | 6.38 x | 12.4 x | 46.3 x |
| Nbr of stocks (in thousands) | 202,449 | 202,449 | - | - |
| Reference price 2 | 27.18 | 20.19 | 20.19 | 20.19 |
| Announcement Date | 15/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | 1.14 | 100.2 | 310.3 |
| EBITDA 1 | - | - | -305 | -246 | -85 |
| EBIT 1 | - | -222 | -314 | -313.5 | -229 |
| Operating Margin | - | - | -27,543.86% | -312.81% | -73.8% |
| Earnings before Tax (EBT) 1 | - | -249.4 | -326 | -336 | -256 |
| Net income 1 | -725.2 | -249.4 | -326 | -336 | -256 |
| Net margin | - | - | -28,596.49% | -335.26% | -82.5% |
| EPS 2 | - | -1.250 | -1.610 | -1.661 | -1.266 |
| Free Cash Flow 1 | - | -275.7 | -268.5 | -243.5 | -231 |
| FCF margin | - | - | -23,552.63% | -242.96% | -74.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 24/04/23 | 15/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S2 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) 1 | -170 |
| Net income 1 | -170 |
| Net margin | - |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 15/03/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 11 |
| Net Cash position 1 | - | - | 499 | 264 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.1294 x |
| Free Cash Flow 1 | - | -276 | -269 | -244 | -231 |
| ROE (net income / shareholders' equity) | - | -25.5% | -41.6% | -97.6% | -1,465% |
| ROA (Net income/ Total Assets) | - | -22.3% | - | -23.5% | - |
| Assets 1 | - | 1,118 | - | 1,430 | - |
| Book Value Per Share 2 | - | 5.040 | 3.160 | 1.630 | 0.4400 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 85.8 | 80 | 43 | 74 |
| Capex / Sales | - | - | 7,017.54% | 42.91% | 23.85% |
| Announcement Date | 24/04/23 | 15/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
20.19
CNY
Average target price
27.73
CNY
Spread / Average Target
+37.32%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.75% | 562M | |
| +6.58% | 41.61B | |
| -11.57% | 33.32B | |
| +79.15% | 28.8B | |
| -14.73% | 15.61B | |
| -6.00% | 13.27B | |
| -12.55% | 11.46B | |
| +166.50% | 10.06B | |
| -54.80% | 9.09B | |
| +4.19% | 8.9B |
- Stock Market
- Equities
- 2480 Stock
- Financials Beijing Luzhu Biotechnology Co., Ltd.
